Skip Navigation

  1. About Us
    1. Overview
    2. History
    3. Recognition
    4. Offices
  2. Our Practice
    1. Practice Areas
      1. Patents, Utility Models, and Industrial Designs
      2. Trademarks
      3. Copyrights
      4. Corporate, Commercial and Business Law
      5. IP Litigation, Alternative Dispute Resolution
      6. Regulatory Law
      7. Licensing, Tech Transfer & Franchising
      8. Anti-Piracy, Anti-Counterfeiting & Enforcement
    2. Industry Groups
      1. Media, Sports & Entertainment Law Group
      2. Life Science & Pharmaceutical Law Group
  3. Our People
    1. Partners
      1. Sergio L. Olivares, Sr. † (1931-2010)
      2. Sergio L. Olivares, Jr.
      3. Luis C. Schmidt
      4. Cesar Ramos, Jr.
      5. Antonio Belaunzaran
      6. Gustavo A. Alcocer
      7. Jose Ignacio De Santiago
      8. Alejandro Luna
      9. Alonso Camargo
      10. Daniel Sanchez
    2. Associates (A - M)
      1. Osvaldo Amaral
      2. Armando Arenas
      3. Sofía Arroyo
      4. Guillermo Ballesteros
      5. Varinia Calleros
      6. Abraham Diaz
      7. Georgina Flores
      8. Pedro Herrera
      9. Carlos Maya
    3. Associates (N - Z)
      1. Mauricio Narváez
      2. Víctor Ramírez
      3. Sergio Rangel
      4. Maria del Carmen Sada
      5. Juan Luis Serrano
      6. Guillermo Treviño
      7. Carlos Woodworth
    4. All Attorneys / Engineers
    5. Firm Administration
  4. Knowledge & Resources
    1. Articles
      1. Trademark Law Articles
        1. Use requirements
        2. Approach to composite marks changed, again
        3. Life Sciences Handbook 2011 - Country Q&A
        4. Mexico should accept secondary meaning
        5. Getting the Deal Through - Trademarks 2011
        6. Pharmaceutical Trademarks 2010/2011 - A Global Guide
        7. No legal basis for banning names derived from INNs
        8. How Latin America tackles cutting-edge IP issues
        9. Specialised IP court corrects IMPI
        10. Protecting trade dress
        11. 43 more items...
      2. Patent Law Articles
        1. Getting the Deal Through - Patents 2012
        2. Surge of Patent Application Final Rejections Provides Unique Opportunity for Patent Precent Making
        3. Mexico issues regulations to approve biologic drugs
        4. Latin America Roundtable
        5. New regulations pending
        6. The International Comparative Guide
        7. Marketing authorization for pharmaceutical
        8. Approval of follow-on biologics in Mexico
        9. Mexican Linkage Gazette April 2011
        10. Patent Prosecution Highway in Mexico
        11. 37 more items...
      3. Copyright Law Articles
        1. Advertising in social media networks
        2. Technology challenges digital rights
        3. Exceptions to copyright protection and the permitted uses of copyright works in the hi-tech and digital sectors
        4. Derechos sobre producción audiovisual
        5. How Latin America tackles cutting-edge IP issues
        6. Copyright Litigation 2010
        7. Legislation and enforcement - Copyrights 2010
        8. Valuing folklore
        9. Protecting novel ideas
        10. Mexico's fair use balancing act
        11. 100 more items...
      4. Corporate Law Articles
        1. Mexico issues Personal Data Protection Rules
        2. How data affects innovation
        3. A practical cross-border
        4. New registry for security interests
        5. The International Comparative Legal Guide to: Merger Control 2011
        6. The International Comparative Legal Guide to: Merger Control 2010
        7. Due diligence issues to consider in M&A
        8. Income expectations in licensing
        9. The reasons for valuation
        10. Amendments proposed to franchise regulation
      5. IP Litigation, ADR Articles
        1. Scope of new specialised courts widened
        2. Reform of preliminary injunctions
        3. Mexican Patent Office excludes Formulation Patents from Linkage Gazette
        4. Mexico gets ready to approve biocomparable drugs
        5. Mexico's hotel for the stars highlights power in the name
        6. Supreme Court upholds the worth of formulation patents
        7. Getting the Deal Through - Patents 2010
        8. Getting the Deal Through Trademarks 2010
        9. Trademark enforcement
        10. Venues for appealing IMPI decisions
        11. 15 more items...
      6. Regulatory Law Articles
        1. Recent amendment to the Federal Law for Consumer Protection
        2. Amendments to the Federal Law for Consumer Protection
        3. Mexico issues Personal Data Protection Rules
        4. New Regulations Pending
        5. Marketing authorization for pharmaceutical products to foreign applicants
        6. Data Package Exclusivity (DPE)
        7. Supreme Court upholds the worth of formulation patents
        8. Pharmaceutical trademarks
        9. Framework for biotherapeutic products established
        10. Pharmaceutical Advertising 2009
        11. 4 more items...
      7. Licensing, Tech Transfer Articles
        1. Creating a secure franchise system
      8. Anti-Piracy, Anti-Counterfeiting Articles
        1. New register against counterfeits
        2. Beat the counterfeiters in Mexico
        3. Battling counterfeits through Customs
        4. Getting the Deal Through Trademarks 2010
        5. Enforcing plant variety rights in Mexico
        6. Pharmaceutical Trademarks 2009
        7. Internet Issues
        8. Anti-counterfeiting 2009
        9. Vegetal variety rights enforced
        10. New Customs rules lead to seizures
        11. 3 more items...
      9. Media, Sports & Entertainment Focused Articles
        1. Advertising in social media networks
        2. Whither Rental Rights?
        3. Improved protection for personalities
      10. Life Sciences Focused Articles
        1. Latin America Roundtable
        2. New regulations pending
        3. The International Comparative
        4. Approval of follow-on biologics in Mexico
        5. Global Pharmaceutical Linkage Regulations:
        6. Life Sciences Handbook 2011 - Country Q&A
        7. Supreme Court upholds the worth of formulation patents
        8. Repercussions expected on medicine advertising campaign in Mexico
        9. Framework for biotherapeutic products established
        10. Pharmaceutical Trademarks 2009
        11. 1 more item...
    2. Webinar Archive
      1. Webinar - Changes to Mexican Patent and Healthcare Laws for Life Sciences
      2. Webinar - Digital Rights Issues in Copyright Law
      3. Webinar - Data Package Exclusivity Rights in Latin America
    3. Recognition
    4. News
      1. Mexico subscribes Madrid Protocol
      2. Presumed Guilty - How can a law firm help win an Emmy?
      3. New rules came in force to speed timeframes in administrative appeal proceedings
      4. Recent reforms to the Mexican Industrial Property Law dealing with trademark priority rights
      5. Olivares & Cia. ranking
      6. Data Package Exclusivity (DPE)
      7. Mr. Sergio Olivares Sr's Passing
      8. Pharma Linkage Regulations Supreme Court Decision
      9. Managing IP magazine has recognized Olivares & Cia. as the leading firm for patent work in Mexico
      10. Mexican Congress amends the Patent Law
      11. 1 more item...
  5. Events
  6. Offices
  7. Contact Us
  8. Quick guide to Mexico’s regulatory system
    1. Patent regulatory overview
    2. Trademark regulatory overview
    3. Copyright regulatory overview
    4. Corporate & Commercial Regulatory overview

Home » Quick guide to Mexico’s regulatory system » Corporate & Commercial Regulatory overview

Corporate & Commercial Regulatory overview

International Comparative Legal Guide to: Merger Control 2012

 

1          Relevant Authorities and Legislation

1.1       Who is/are the relevant merger authority(ies)?

The Federal Competition Commission, which is an administrative agency independent from the Mexican Ministry of Economy, has technical and operational autonomy to issue its resolutions.  The Commission is integrated to exercise merger authority by public officials, divisions and administrative units, of which the main authority is the Commission in Plenary session, comprised of 5 commissioners, including the Commission President.  Resolutions are issued by majority votes of its members and exceptionally by qualified majority in accordance with the Law.

1.2       What is the merger legislation?

Listed in order of hierarchy: (i) Article 28th of the Mexican Constitution, which establishes the antitrust prohibition and the monopoly exception regime in the case of intellectual property (patents, trademarks and copyrights) and certain state monopolies (oil, electricity, postal service, among others); (ii) international treaties to which Mexico is a party, containing antitrust provisions, including, among others, NAFTA and EUFTA; (iii) the Federal Economic Competition Law (the “Law”) and its regulations (iv) the Industrial Property Law; (iv) the Copyright Law; (v) the Foreign Investment Law; and (vi) the Federal Criminal Code and (vii) the Federal Tax Code.

1.3       Is there any other relevant legislation for foreign mergers?

Not in terms of Economic Competition, but requirements and limitations apply with respect to foreign investment for certain industry sectors.

1.4       Is there any other relevant legislation for mergers in particular sectors?

Not in terms of Economic Competition, but requirements and limitations apply with respect to foreign investment for certain industry sectors.

 

2          Transactions Caught by Merger Control Legislation  

2.1       Which types of transaction are caught – in particular, how is the concept of "control" defined?

The types of transactions caught under merger control provisions are subject to threshold tests related to the underlying value of each transaction.  The Law defines a concentration as any merger, control acquisition or any act resulting in the concentration of two different entities, including trust or assets in general among and between competitors, suppliers, customers or any economic agents.

Notwithstanding the foregoing, the Commission is able to challenge, suspend and sanction, subject to express criteria, any concentration with the purpose of diminishing, damaging or not allowing competition, with respect to identical, similar or substantially similar goods and services.

The Commission may issue a restrictive order not to execute the underlying transaction, until a favourable resolution is issued, during a term of 10 days following the filing of the concentration notice.

Although control is not a defined term, the Law regulation applies a control test as it relates to:

i.          the merger control notice, establishing that notice shall be filed prior to exercising direct or indirect control in-fact or by law; and

ii.         allowing for the notice to be made by the party acquiring control of the corporation, in absence of the parties directly involved in the underlying transaction.

2.2       Can the acquisition of a minority shareholding amount to a "merger"?

The acquisition of a minority shareholding does not amount to a merger; however, if such acquisition is within the scenarios and thresholds specified under question 2.5 it would be subject to notice to the Commission.

2.3       Are joint ventures subject to merger control?

Yes, please refer to questions 2.1 and 2.4.

2.4       What are the jurisdictional thresholds for application of merger control?

Based on the foregoing, the following transactions are subject to prior notice:

1.         When the transaction, irrespective of the place of execution, results in the direct or indirect amount in Mexico being the equivalent to more than 18M times the minimum general daily wage applicable in Mexico City (MGDW), $1,076,760,000.00 M.N., Pesos.

2.         When the origins of the transaction imply an aggregate of 35% or more of the assets or shares of a party, whose annual assets in Mexico or annual sales which originated in Mexico, are equal to more than 18M times the MGDW, $1,076,760,000.00 M.N., Pesos.

3.         When the origins the transaction imply an aggregation in Mexico of assets or capital stock which amount to more than the equivalent of 8.4M times the MGDW $502,488,000.00 M.N., Pesos and two or more entities participate, which assets or annual sales volume on an individual or aggregate basis are equal to more than 48M times MGDW, $2,871,360,000.00 M.N., Pesos.

For reference purposes, as of 31 August 2011 the foreign exchange rate is $12.48 Pesos per Dollar, as quoted by Mexico’s Central Bank on the Official Gazette of the Federation (Diario Oficial de la Federación) and the MGDW is $59.82 Pesos.

2.5       Does merger control apply in the absence of a substantive overlap?

Merger control applies in the scenarios and thresholds described above, regardless of whether monopolistic conduct has occurred, which in turn may result in an antitrust investigation by the Commission’s discretionary authority or upon a third party claim.

2.6       In what circumstances is it likely that transactions between parties outside Mexico ("foreign to foreign" transactions) would be caught by your merger control legislation?

Merger control applies when the transaction, irrespective of the place of execution, results in the direct or indirect amount in Mexico (either as capital stock, assets or sales, respectively) being the equivalent to the threshold referred to in question 2.4 above.

2.7       Please describe any mechanisms whereby the operation of the jurisdictional thresholds may be overridden by other provisions.

There are none.

2.8       Where a merger takes place in stages, what principles are applied in order to identify whether the various stages constitute a single transaction or a series of transactions? 

The principles that apply are the relevant market, the parties involved, the term between the stages and type of transaction.

.

3          Notification and its Impact on the Transaction Timetable 

3.1       Where the jurisdictional thresholds are met, is notification compulsory and is there a deadline for notification?

Yes, notification is compulsory when the thresholds are met, and must be made prior to the implementation of the underlying transaction (for a more detailed deadline schedule, see our response to question 3.5).

3.2       Please describe any exceptions where, even though the jurisdictional thresholds are met, clearance is not required.

Transactions are exempt from clearance even if they exceed the monetary thresholds (please refer to question 2.4) when: (i) the transaction implies a corporate reorganisation in which the underlying parties belong to the same relative market and no third party is involved in such reorganisation; (ii) a stockholder increases its participation in the capital stock of a corporation in which it has held control since its incorporation or when the Commission has previously authorised the acquisition of such control prior to the capital stock increase; (iii) at inception of any type of trust (for management or guaranty) based on which a party contributes its assets, as long as such contribution is not for the benefit of any person other than the assignee or the trustee; however, if the guaranty trust is enforced notice must filed in accordance with the thresholds mentioned in our response to question 2.4; (iv) transactions related to stocks, shares or trust certificates which are implemented abroad have as counterparties either foreign companies or non-residents (for Mexican tax purposes), as long as the underlying companies do not acquire control in Mexican companies or accumulate in Mexico stocks, shares or trusts certificates, or any other asset in addition to those held, directly or indirectly, before the transaction; (v) the acquirer is an equity investment company and the purpose of the transaction is to acquire shares, debentures, securities, credit instruments or equity participations with proceeds obtained from a public offering of the investment company’s stock, except if as a result of the transaction such investment company has a meaningful influence in the decision making of the relevant economic agent; (vi) in the acquisition of shares, securities, credit instruments or equity participations of any company or in instruments which underlying assets are stocks of a public traded company, when the transaction does not allow the purchaser to acquire 10% or more of such assets, and additionally, the purchaser does not have authority to: a) appoint or revoke board members of the issuing company; b) directly or indirectly impose decisions at the shareholders’ or partners’ meetings or equivalent management bodies; c) maintain ownership of rights that allows them to, directly or indirectly, vote the shares of 10% or more of a company’s capital stock; or d) manage or directly or indirectly influence the management, operation, strategy or main policies of a company, either through  ownership of securities, by contract or otherwise; and (vii) they acquire stock, shares or trust certificates or equity participations in one or more investment funds with speculation purposes (portfolio investment) where such funds do not have any investments in companies or assets in which they participate or invest, or where they are employed in the same relevant market with the relevant economic agent.

 

3.3       Where a merger technically requires notification and clearance, what are the risks of not filing?

The Commission is entitled to: (i) order the cancellation of the underlying merger; (ii) order the partial or total divestment of assets acquired; and (iii) impose penalties of up to 5% of the party’s income.  

3.4       Is it possible to carve out local completion of a merger to avoid delaying global completion?

Yes, it is possible to carve out local competition through the establishment of conditions precedents applicable to the perfection of mergers in Mexico, such as the issuance of a favourable resolution by the Commission.

3.5       At what stage in the transaction timetable can the notification be filed?

Notification must be filed at any time before any of the following events occur:

i.          the underlying act is perfected in accordance with the applicable legislation or, should it be the case, the condition precedent to which such act is subject, is fulfilled;

ii.         control is acquired de facto or de jure, or exercised directly or indirectly over another entity; or before assets, participation in trusts, partners’ capital contributions or shares of another party are acquired de facto or de jure;

iii.        a merger agreement is signed between the parties to it without the condition that clearance of merger notice must be obtained prior to effectiveness; or

iv.        in the case of a succession of acts, before executing the last one that would result in exceeding the applicable threshold amounts.

With respect to mergers resulting from acts executed abroad, these must be notified before they have legal or material effects within Mexican territory.

3.6       What is the timeframe for scrutiny of the merger by the merger authority? What are the main stages in the regulatory process?  Can the timeframe be suspended by the authority?

Within the 15 days following filing date, the Commission is entitled to request additional information or documentation, which must be delivered by the interested parties within the 20 days following the request.  This timeframe may only be extended once, decided on a case-by-case basis, for 20 days at the parties’ request, if the complexity of the case or the volume of information requested justifies it.  After the documentation delivery process is completed, the Commission has a 35-day term to issue its resolution; however, the President of the Commission is entitled to extend each Commission term for up to 40 days, but this only happens in extraordinarily complex transactions.

3.7       Is there any prohibition on completing the transaction before clearance is received or any compulsory waiting period has ended?  What are the risks in completing before clearance is received?

If within the ten days of the filing date the Commission does not order the parties to refrain from executing the underlying merger until a favourable resolution is issued, then the parties, at their own risk, can execute the merger.  Provided, however, that, if such order is not issued within such a term, it shall not be interpreted as an implied authorisation for the execution of the underlying merger, unless the term granted to the Commission for issuance of its resolution expires, in which case it shall be interpreted as if the Commission has no objection against the merger.

As for the risks of executing the merger before clearance is received, the interested parties are subject to those sanctions specified in response to question 3.3.

3.8       Where notification is required, is there a prescribed format?

The notice shall be made in writing through a free form writ, to which a copy of the underlying agreements shall be enclosed.  Such writ must include the names or corporate names of the corresponding parties, the financial statements of the last fiscal year, their market share and any additional information through which the merger is documented.

3.9       Is there a short form or accelerated procedure for any types of mergers?

The Law does not provide for an accelerated procedure per se; however, if, at the time of filing the notice, the parties provide as much information as available, such as analysis, reports, evidence, etc. to support the fact that such a merger will notably not result in diminishing, damaging or preventing competition, then the Commission is granted a term of 15 days to issue its resolution.  If such term is not extended by the President of the Commission and expires, it shall be interpreted as if the Commission has no objection against the merger.

3.10     Who is responsible for making the notification and are there any filing fees?

The parties participating in the underlying merger are responsible for filing the notification and appointing a sole representative.  In addition, when the parties cannot, for any reason, provide the notice, the merging entity, the party acquiring control of the corporation, the entity intending to enter into the transactions or to aggregate the shares, equity interest, trust interests or assets, is responsible for filing the notice.

(As of January 2011 there are no filing fees.) 

.

4          Substantive Assessment of the Merger and Outcome of the Process 

4.1       What is the substantive test against which a merger will be assessed?  Are non-competition issues taken into account?

The parties are subject to scrutiny in order to determine if, as a result of the concentration the parties are able to fix prices, restrict in a material way competitors’ access to the relevant market or engage in illicit monopolistic practices.  Non-competition issues are taken into account on a case-by-case basis (i.e. scope of the non-competition provision, term of the obligation not to compete, size of the relevant market, among others).

4.2       What is the scope for the involvement of third parties (or complainants) in the regulatory scrutiny process?

The Law allows for third party written complaints, in the event of absolute monopolistic practices (absolute monopolistic practices are contracts, agreements, arrangements, or combinations among competitive economic agents, whose aim or effect are any of the following: (i) to fix, raise, agree upon or manipulate the purchase or sale price of the goods or services supplied or demanded in the markets, or to exchange information with the same aim or effect; (ii) to establish the obligation to produce, process, distribute or market only a restricted or limited amount of goods, or to render a specific volume, number, or frequency of restricted or limited services; (iii) to divide, distribute, assign or impose portions or segments of the current or potential market of goods and services, by means of a determinable group of customers, suppliers, time or spaces; or (iv) to establish, agree upon or coordinate bids or to abstain from bids, tenders, public auctions or bidding), for affected party complaints in the case of other monopolistic practices (subject to verification of articles 11, 12 and 13 of the Law, relative monopolistic practices are deemed to be those acts, contracts, agreements or combinations, which aim or have the effect of improperly displacing other agents from the market, substantially hindering their access thereto, or establishing exclusive advantages in favour of one or several entities or individuals), or transactions subject to merger control.  Such claims need to be filed against the alleged responsible party, with a description of the facts deemed in violation of the Law and the concepts for which the claimant has suffered, or that will result in the presumption of damages, if any.

Once that the claim is filed, and during the investigation process, the Commission will not allow access to the claim file, and, during the process, only those entities with legal standing will have access to such information, except for the information identified as confidential.

4.3       What information gathering powers does the regulator enjoy in relation to the scrutiny of a merger?

When exercising its powers, the Commission may request from the relevant parties information deemed material (including documentation, books and records, information generated in electronic, optic or in any other media or technology), as well as summon those involved in the corresponding cases for purposes of merger scrutiny, request and verify information from third parties, including competitors and clients, among others.  Additionally, the Commission has the power to conduct verification visits at its discretion, with the assistance of the public force and federal, state or municipal authority.

Notwithstanding the foregoing, if a merger is approved the Commission is not authorised to initiate an investigation procedure, with the exception of those cases when such resolution was obtained based on false information.

4.4       During the regulatory process, what provision is there for the protection of commercially sensitive information?

Any information filed before the Commission or obtained by it during an investigation process will be classified as reserved, confidential or public.  Reserved information is that available only to those entities with legal standing in the investigation process; confidential information means information that, if disclosed to any entity with legal standing in the investigation process, such disclosure will result in damages to the disclosing party.  Confidential information will only be treated as such if the disclosing party requests so.  The Commission, each of its commissioners on an individual basis, its Executive Secretary and any public officer of the Commission must refrain from revealing reserved or confidential information related to the files or administrative procedures which are part of a legal proceeding and that may cause damage to the underlying parties until the investigated party has been notified with a resolution, on the understanding that the information will continue to be classified or confidential. 

5          The End of the Process: Remedies, Appeals and Enforcement

5.1       How does the regulatory process end?

The regulatory process concludes with a resolution by the Commission, and may end at different stages, depending on the process: 35 days (which may be extended) and, when merger control notice is given and parties demonstrate that the merger will not result in diminishing, damaging or obstructing free competition, the Commission will resolve within 15 days (which may be extended), following the admission date of the notice, respectively.  If the Commission has not resolved after the applicable term expires, the notice is deemed not to be subject to objection by the Commission.  This final resolution is subject to appeal.

5.2       Where competition problems are identified, is it possible to negotiate "remedies" which are acceptable to the parties?

Yes, provided that such remedies are agreed upon, then parties are notified to the Commission, prior to the issuance of the resolution.  The Commission may notify either formally or informally the criteria that needs to be met: i.e. excessive terms for non-compete provisions, which parties may reduce to comply with the set criteria and allow for the favourable resolution to be issued.

5.3       At what stage in the process can the negotiation of remedies be commenced? Please describe any relevant procedural steps and deadlines.

During the assessment period and before the resolution is issued, the negotiation of remedies can be commenced.  There is no particular procedure to negotiate remedies which shall be agreed upon before the resolution is issued.

5.4       If a divestment remedy is required, does the merger authority have a standard approach to the terms and conditions to be applied to the divestment?

No.  The divestment remedy is customarily resolved as a condition precedent to the clearing the merger notice.

5.5       Can the parties complete the merger before the remedies have been complied with?

The parties may execute the underlying transaction, assuming any liability resulting from non-compliance of the Law.  In the case of transactions that require filing before the public registry, filing is conditional upon a favourable resolution of the Commission.

5.6       How are any negotiated remedies enforced?

Negotiated remedies need to be complied with in order for a favourable resolution to be issued.

5.7       Will a clearance decision cover ancillary restrictions?

No, ancillary restrictions are customarily resolved as conditions to the clearance decision.

5.8       Can a decision on merger clearance be appealed?

Yes, decisions can be appealed.

5.9       Is there a time limit for enforcement of merger control legislation?

The authority of the Commission to initiate investigations that may result in the application of sanctions expire in a term of 5 years following the date the underlying conduct was performed.  The authority of the Commission to initiate a criminal action expires six and a half years after issuance by the Commission of the resolution concluding that a party is liable for conducting monopolistic practices.  In the case of merger control, the transactions not subject to notice cannot be investigated after a one year term, following the date of completion of the transaction.

.

6          Miscellaneous

6.1       To what extent does the merger authority in Mexico liaise with those in other jurisdictions?

Mexico is a party to international treaties and arrangements to cooperate in competition enforcement matters, among which are NAFTA, UEFTA, and treaties with the USA, Japan, Korea and the European Free Trade Association.  Such treaties and arrangements include commitments related to international coordination and cooperation matters.

6.2              Please identify the date as at which your answers are up to date.

August 31, 2011.